Compare Ascendis Pharma A/S (ASND) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs EHang Holdings Ltd - ADR — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while EHang Holdings Ltd - ADR trades at $5.54 (market cap $423.98M). The key difference: Ascendis Pharma A/S is far larger — about 41.8× EHang Holdings Ltd - ADR's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ASND | EH | |
|---|---|---|
Market Cap | $17.74B | $423.98M |
Sector | Health | Industrials |
52-Week High | $277.18 | $19.99 |
52-Week Low | $163.32 | $5.52 |
Enterprise Value | $18.11B | $363.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EHang Holdings (EH) trades at $5.59, down 3.45% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $418M, flat year-over-year but sharply lower sequentially due to delivery timing. Despite a high gross margin of 61.53%, net losses persist with a -77.56% margin. Cash flow improved in 2024 but reversed negative in 2025. Recent news highlights volatility, including an 18% surge on June 15, 2026, followed by concerns over Q1 sales missing forecasts.
The outlook remains speculative with significant execution risks amid ongoing losses, though analyst consensus suggests moderate upside to a $6.97 target. Investment opportunity hinges on commercial scaling of eVTOL operations, but high cash burn and competitive pressures pose substantial risks. Sentiment is divided, with 40% sell ratings reflecting skepticism over near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
